These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-000279-16 Phase III Clinical Study of Allogeneic Stem Cell Transplantation with Reduced Conditioning (RICT) versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission not-yet-due
Ongoing 2005-001008-37 Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy not-yet-due
Not reported 2005-003867-21 Induction chemotherapy with docetaxel and cisplatin followed by radiotherapy concomitant with cetuximab for locally advanced stage III non-small cell lung cancer- amulticentre, open label non-randomis... 2007-08-11 due-trials
Completed, but no date, and reported results Terminated 2005-005544-79 Adalimumab (Humira) as add-on therapy in the treatment of patients with severe persistent therapy resistant asthma bad-data
Completed, but no date Terminated 2006-000487-92 A Phase II, Randomised, Double Blind, Placebo Controlled Study examining the suitability of Phenytoin Sodium Topical Gel in the treatement of Venous Ulcers bad-data
Ongoing, reported early 2008-005657-38 Transversus Abdominis Plane Block for Analgesia in Renal Transplantation: A Randomised Controlled Trial not-yet-due
Exempt 2008-005871-92 En fas 1 studie av effekt av Tysabri (natalizumab), en IgG4 humaniserad monoklonal antikropp specifik mot VLA-4 (integrin alfa-4), administrerad som infusion 1 gång/månad under 3 månader hos patiente... not-yet-due
Ongoing 2009-009039-32 Abciximab versus Eptifibatide versus Bivalirudin during PCI in patients with acute coronary syndromes not-yet-due
Completed, but no date 2009-015926-13 Treatment of Huntington´s disease with OSU 6162 - a pilot study bad-data
Ongoing 2009-016783-37 The Effects of 18-Month Replacement with a Very Low Fixed Dose vs. Standard Dose of Growth Hormone (GH) on Insulin Sensitivity, Body Composition, Bone Mass, Lipids, Muscle Strength and Quality of Life... not-yet-due
Ongoing 2010-022065-10 Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within the Swedish Association... not-yet-due
Ongoing 2011-003418-18 A Randomised, Double Blind, Placebo Controlled, Multi-centre, Parallel Group, Interventional Study of Mesalazine (Asacol®) Treatment in IBS and the Evaluation of Rectal Inflammatory Status using the M... not-yet-due
Completed, reported early 2013-000564-29 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases 2023-03-11 not-yet-due
Reported results 2014-001332-11 Aspirin for Optimising Pregnancy Outcome in Pregestational Diabetes: Pilot for The IRELAND Study (Investigating the Role of Early Low-dose Aspirin iN preexisting Diabetes) 2016-12-06 due-trials
Reported results Terminated 2014-002988-16 The Use of Milrinone in Neonates with Persistent Pulmonary Hypertension of the Newborn: A Randomised Controlled Trial Pilot Study (MINT 1) 2021-02-26 due-trials
Reported results 2015-000499-89 To measure the effects of Aspirin loading dose of 300mgs in healthy controls using AA LTA and the Dynamic Platelet Function Assay (DPFA). 2017-06-20 due-trials
Ongoing 2015-002096-14 Examine whether treatment with methylphenidate facilitates work rehabilitation for persons with long-term pain and mental fatigue after traumatic brain injury. Undersöka om behandling med metylfeni... not-yet-due
Reported results 2015-004526-33 A Randomised Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score 2020-08-05 due-trials
Reported results 2015-005421-40 The use of topical Glyceryl Trinitrate (GTN) and eccentric exercises in the treatment of mid portion Achilles Tendinopathy: a randomised placebo controlled trial 2018-12-01 due-trials
Reported results Terminated 2016-000167-16 DIsulfiram REsponse as add-on to ChemoTherapy in recurrent Glioblastoma: A randomized controlled trial 2021-01-15 due-trials
Reported results Terminated 2016-001528-69 PENICILLIN FOR THE EMERGENCY DEPARTMENT-DIRECTED OUTPATIENT TREATMENT OF CELLULITIS (PEDOCELL) STUDY: A NON-INFERIORITY ADAPTIVE RANDOMISED CONTROLLED TRIAL. 2020-04-07 due-trials
Ongoing 2016-001906-41 A randomised control trial of intra articular injectates in knee osteoarthritis: A comparison of corticosteroid (Methylprednisolone Acetate) and NSAID (Ketorolac tromethamine) injections not-yet-due
Completed, but no date 2016-002114-50 A multicenter phase II open label study to evaluate efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma bad-data
Exempt 2016-002728-94 A phase I/II, open-label study of safety, immune activation and efficacy of histamine dihydrochloride and low-dose interleukin-2 in adult tyrosine kinase inhibitor-treated patients with chronic myeloi... not-yet-due
Reported results 2016-003181-12 Can sonographic assessment of pulmonary vascular reactivity following maternal hyperoxygenation therapy predict neonatal outcome in fetuses at risk of pulmonary hypertension? 2018-07-22 due-trials
Completed, but no date, and reported results Terminated 2016-004471-46 Drug level and Investigation of Novel Substances Indicated Downstream Effect in (INSIDE) glioblastoma bad-data
Ongoing 2016-005225-37 The ASTEROID trial - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotactic Body radiotherapy (SBRT) in patients ... not-yet-due
Ongoing 2017-001499-43 Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in patients with acute coronary syndrome (TACSI trial) not-yet-due
Other 2017-003830-97 Effects of an Opiod Sparing Care Pathway for Patients undergoing Obesity Surgery not-yet-due
Exempt 2017-004200-21 A phase Ib/II randomized double-blind placebo controlled trial evaluating the effect of nivolumab for patients with in-transit melanoma metastases treated with isolated limb perfusion not-yet-due
Completed, but no date, and reported results 2017-004898-14 See down below. Maternella serum koncentrationen av magnesium under 24 timmar efter en bolusdos (6g) av magnesiumsulfat vid hotande förtidsbörd bad-data
Not reported 2018-001021-10 Brodalumab in a randomised, open, phase IV study evaluating clinical efficacy in psoriasis patients switching from TNF-alpha inhibitor treatment 2020-06-18 due-trials
Completed, but no date Terminated 2019-002548-26 Can Pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis? A pragmatic, randomised, placebo controlled trial bad-data
Ongoing 2020-000233-41 Labour induction in an outpatient setting - a multicenter randomized controlled trial. OPTION - OutPatienT InductiON not-yet-due
Reported results 2020-001391-15 A randomized double-blind placebo-controlled, pilot trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. 2021-04-12 due-trials
Exempt 2020-003188-24 A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination with Ipilimumab and Nivolumab in Patients with Uveal Melanoma Metastases not-yet-due
Ongoing 2020-005176-35 OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure (OPRA-HF) not-yet-due
Ongoing, reported early 2021-000275-36 Prevention of Glucocorticoid induced impairment of bone metabolism – A Randomized, Placebo-Controlled, Single Centre Clinical Trial not-yet-due
Ongoing 2021-001806-32 Influence of Argipressin on blood loss and inflammatory response during hepatic resection; a double blinded, randomized, placebo-controlled trial not-yet-due
Completed, reported early Terminated 2021-004600-17 The use of Sildenafil in Neonates with Down Syndrome to Reduce Pulmonary Vascular Resistance. 2023-11-02 not-yet-due